TransMedics Group (TMDX) is in focus after its Organ Care System gained broader traction, supported by multiple FDA approvals, a shift toward a recurring full service model and plans for kidney and international market expansion.

Despite the recent 7 day share price return of a 6.74% decline and a softer 30 day move, TransMedics Group’s 1 year total shareholder return of 76.33% and 5 year total shareholder return of 332.72% point to strong longer term momentum.

If this transplant technology story has caught your interest, it could be a good moment to broaden your watchlist with our screener of 25 healthcare AI stocks.

With TMDX trading at US$129.60, an implied 11% gap to the average analyst target of US$144.20 and an estimated intrinsic value suggesting a larger discount, you have to ask: is there still a buying opportunity here or is the market already pricing in future growth?

Most Popular Narrative: 10.1% Undervalued

At $129.60, the most followed narrative sees TransMedics Group trading below an implied fair value of about $144.20, with that gap hinging on sustained growth and profitability shifts over time.

Development of a recurring, service-driven revenue model, including logistics, digital ecosystem, and service contracts, enables more predictable and stable cash flows, which improves operating leverage and could drive higher long-term net margins.

Curious what sits behind that margin story. The narrative describes faster top line expansion, rising profitability, and a premium earnings multiple. It is useful to see which specific growth, margin, and valuation assumptions would need to align for that fair value to be supported.

Result: Fair Value of $144.20 (UNDERVALUED)

However, that upside story could be knocked off course if competitor devices gain share faster than expected or if international expansion struggles with regulation and reimbursement.

Another Take Using Market Pricing

Our DCF work suggests TMDX could be worth around $265.73 per share, which is very different to a P/E based view. On a P/E of 48.3x versus an industry average of 30.6x and a fair ratio of 23.8x, the market is already asking you to pay a rich price for growth that still needs to be delivered. So, is this a margin of safety or a margin of error?

Build Your Own TransMedics Group Narrative

If you look at these numbers and reach a different conclusion, or simply prefer to test your own assumptions quickly, you can build a personalized TransMedics view in just a few minutes, starting with Do it your way.

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding TransMedics Group.

Looking for more investment ideas?

If you are weighing up what to do next, this is the moment to widen your opportunity set with a few targeted stock ideas beyond TransMedics.

• Spot potential bargains early by scanning our list of screener containing 25 high quality undiscovered gems that screens for companies with strong fundamentals that many investors may be overlooking.
• Strengthen your core holdings by checking companies in our solid balance sheet and fundamentals stocks screener (46 results) that filters for firms with robust financial footing and cleaner balance sheets.
• Dial down portfolio stress by reviewing 80 resilient stocks with low risk scores that focuses on businesses with lower risk scores based on our model.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.